title: Intensifying daunorubicin in induction for patients with core binding factor leukemia.
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Dobashi
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Asai
authors.forename: Shingo
authors.initials: S
authors.lastname: Yano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Osawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yahagi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takei
authors.forename: Katsuki
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Saito
authors.forename: Noriko
authors.initials: N
authors.lastname: Usui
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin